Zhu Fu-Gang, Kandimalla Ekambar R, Yu Dong, Tang Jimmy X, Agrawal Sudhir
Hybridon, Inc., 345 Vassar Street, Cambridge, MA 02139, USA.
Int Immunopharmacol. 2004 Jul;4(7):851-62. doi: 10.1016/j.intimp.2004.03.009.
Oligodeoxynucleotides containing unmethylated CpG dinucleotides (CpG DNAs) prevent development of T-helper type 2 (Th2) immune responses and reverse established allergic responses in mouse models. We recently reported that second-generation immunomodulatory oligonucleotides (IMOs) containing novel structures (immunomers) and a synthetic immunostimulatory CpR (R=2'-deoxy-7-deazguanosine) motif induce the production of distinct cytokine secretion profiles in vitro and in vivo. In the present study, we evaluated IMOs containing CpG and CpR motifs to modulate allergen-induced Th2 immune responses in prevention and treatment models. Mice sensitized and challenged with ovalbumin (OVA) were treated with a CpG DNA or an IMO by administration either at the time of OVA sensitization (co-administration; prevention) or after establishment of an allergic response (treatment). Spleens, blood, and lungs were collected and analyzed for immune responses. Spleen-cell cultures harvested from OVA-sensitized mice showed a significant decrease in Th2 cytokine levels with a concomitant increase in Th1 cytokine levels only when CpG DNA or IMOs were co-administered with OVA. The co-administration of CpG DNA or IMOs during OVA sensitization significantly reduced serum OVA-specific and total IgE levels in mice. The mice who received CpG DNA or IMOs co-administered with OVA showed a small reduction in serum OVA-specific and total IgG1 levels and a significant increase in serum OVA-specific and total IgG2a levels. Similar results were found in mice with established allergic responses who received IMO treatment. IMO treatment also resulted in strong inhibition of inflammatory cell infiltration and goblet cell hyperplasia in the lungs compared with untreated mice lungs. These data demonstrate that IMOs prevent antigen-induced Th2 immune responses when co-administered to mice during OVA sensitization and that IMOs reverse established allergic responses induced by OVA.
含有未甲基化CpG二核苷酸的寡脱氧核苷酸(CpG DNA)可预防小鼠模型中2型辅助性T细胞(Th2)免疫反应的发展,并逆转已建立的过敏反应。我们最近报道,含有新型结构(免疫体)和合成免疫刺激CpR(R = 2'-脱氧-7-脱氮鸟苷)基序的第二代免疫调节寡核苷酸(IMO)在体外和体内可诱导产生不同的细胞因子分泌谱。在本研究中,我们评估了含有CpG和CpR基序的IMO在预防和治疗模型中对变应原诱导的Th2免疫反应的调节作用。用卵清蛋白(OVA)致敏并激发的小鼠,在OVA致敏时(联合给药;预防)或过敏反应建立后(治疗),通过给药CpG DNA或IMO进行治疗。收集脾脏、血液和肺组织并分析免疫反应。仅当CpG DNA或IMO与OVA联合给药时,从OVA致敏小鼠收获的脾细胞培养物中Th2细胞因子水平显著降低,同时Th1细胞因子水平升高。在OVA致敏期间联合给予CpG DNA或IMO可显著降低小鼠血清OVA特异性和总IgE水平。接受与OVA联合给药的CpG DNA或IMO的小鼠血清OVA特异性和总IgG1水平略有降低,而血清OVA特异性和总IgG2a水平显著升高。在已建立过敏反应的小鼠中接受IMO治疗也发现了类似结果。与未治疗小鼠的肺相比,IMO治疗还导致肺部炎症细胞浸润和杯状细胞增生受到强烈抑制。这些数据表明,在OVA致敏期间与小鼠联合给药时,IMO可预防抗原诱导的Th2免疫反应,并且IMO可逆转由OVA诱导的已建立的过敏反应。